MRI-Guided TULSA Effective at Five Years for Localized Prostate Cancer – Renal and Urology News
Minimally invasive transurethral ultrasound ablation provides disease control without side effects
Minimally invasive transurethral ultrasound ablation provides disease control without side effects
Among other findings, investigators quantified how much of a reduction in total tumor burden is needed in response to presurgical systemic therapy to decrease death…
Study findings raise questions about the value of pelvic lymph node dissection.
In this video, 4 experts discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting.
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.
The EAU Non-neurogenic Female Luts Guidelines aim to provide an overview of the aspects relating to non-neurogenic female LUTS in adult females.
Attaining a tetrafecta composite outcome during radical nephroureterectomy (RNU) does not decrease the risk of cancer recurrence or increase overall
Zach Klaassen and Hanan Goldberg discuss the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC), highlighting the impact of PSMA PET scans on diminishing this…
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.